tradingkey.logo

Bio-Techne Corp

TECH

50.240USD

-0.539-1.06%
收盘 04/25, 16:00美东报价延迟15分钟
7.93B总市值
50.18市盈率 TTM

Bio-Techne Corp

50.240

-0.539-1.06%
关于 Bio-Techne Corp 公司
Bio-Techne Corporation 是一家全球生命科学公司,为研究和临床诊断界提供工具和生物活性试剂。该公司的产品有助于对生物过程以及特定疾病的性质和进展进行科学研究。该公司与 Wilson Wolf 合作,正在开发专门针对 G-Rex 生物反应器的产品,例如培养基和细胞因子。其部门包括蛋白质科学和诊断与基因组学。蛋白质科学部门是生命科学研究、诊断和细胞及基因治疗各个方面所用生物试剂的开发商和制造商。该部门还包括手动和自动蛋白质组学分析工具。诊断与基因组学部门开发和制造诊断产品,包括用于受监管诊断市场的控制品、校准器和诊断检测、基于外泌体的分子诊断检测和组织活检分析。
公司简介
公司代码TECH
公司名称Bio-Techne Corp
上市日期Feb 09, 1989
成立日期1981
CEOMr. Kim Kelderman
员工数量3100
证券类型Ordinary Share
年结日Feb 09
公司地址614 Mckinley Pl N E
城市MINNEAPOLIS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编55413
电话16123798854
网址https://www.bio-techne.com/
公司代码TECH
上市日期Feb 09, 1989
成立日期1981
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
7.13K
+25.77%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
3.19K
+90.01%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Genomics Segment
President - Diagnostics and Genomics Segment
2.98K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
2.14K
+215.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
地区USD
名称
营收
占比
United States
159.91M
53.83%
EMEA, excluding U.K
70.39M
23.70%
Greater China
24.75M
8.33%
APAC, excluding Greater China
19.01M
6.40%
United Kingdom
13.24M
4.46%
Rest of World
9.73M
3.27%
业务
地区
业务USD
名称
营收
占比
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
持股股东
股东统计
占比
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
47.40%
Investment Advisor
44.16%
Hedge Fund
2.25%
Bank and Trust
2.16%
Pension Fund
1.88%
Research Firm
1.54%
Sovereign Wealth Fund
1.27%
Individual Investor
1.04%
Insurance Company
0.23%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1193
162.20M
102.60%
-2.87M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
2023Q1
1206
153.08M
97.33%
-5.18M
2022Q4
1190
153.16M
97.57%
-6.72M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
18.52M
11.72%
+275.81K
+1.51%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.43M
6.6%
+1.23M
+13.34%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.25M
5.85%
+4.60K
+0.05%
Dec 31, 2024
State Street Global Advisors (US)
6.47M
4.09%
+76.69K
+1.20%
Dec 31, 2024
Baron Capital Management, Inc.
4.14M
2.62%
-308.56K
-6.94%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.00M
2.53%
+98.66K
+2.53%
Dec 31, 2024
Neuberger Berman, LLC
3.58M
2.27%
+65.69K
+1.87%
Dec 31, 2024
D. F. Dent & Company, Inc.
3.20M
2.03%
-97.30K
-2.95%
Dec 31, 2024
Atlanta Capital Management Company, L.L.C.
2.95M
1.87%
-40.17K
-1.34%
Dec 31, 2024
Mairs and Power, Inc.
2.82M
1.78%
-24.98K
-0.88%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Global X Genomics & Biotechnology ETF
4.16%
Invesco Biotechnology & Genome ETF
2.26%
Tema Monopolies and Oligopolies ETF
1.9%
VanEck Biotech ETF
1.79%
Hilton Small-MidCap Opportunity ETF
1.77%
Thrivent Small-Mid Cap ESG ETF
1.75%
iShares Health Innovation Active ETF
1.72%
Neuberger Berman Small-Mid Cap ETF
1.49%
Invesco S&P 500 Equal Weight Health Care ETF
1.27%
American Century Mid Cap Growth Impact ETF
0.98%
查看更多
Global X Genomics & Biotechnology ETF
占比4.16%
Invesco Biotechnology & Genome ETF
占比2.26%
Tema Monopolies and Oligopolies ETF
占比1.9%
VanEck Biotech ETF
占比1.79%
Hilton Small-MidCap Opportunity ETF
占比1.77%
Thrivent Small-Mid Cap ESG ETF
占比1.75%
iShares Health Innovation Active ETF
占比1.72%
Neuberger Berman Small-Mid Cap ETF
占比1.49%
Invesco S&P 500 Equal Weight Health Care ETF
占比1.27%
American Century Mid Cap Growth Impact ETF
占比0.98%
分红派息
近5年累计派现 249.41M 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
查看更多
拆合股
公告日期
类型
比率
Nov 01, 2022
Split
1>4
公告日期
类型
比率
Nov 01, 2022
Split
1>4
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有